



## AIRC-IFOM Joint Meeting 2024 From Biological Mechanisms to New Therapies

Milano, June 26-27, 2024



### DAY 1 - JUNE 26

---

**08:00** Registration

**08:45** Introduction and greetings

**09:00 - 13.40**

#### SESSION 1: UNDERSTANDING CANCER MECHANISMS

**09:00 Keynote Speaker**

**John Dick**, Princess Margaret Cancer Center, University Health Network, Toronto  
What makes a stem cell a stem cell and how does it go bad?

**09:35 Chiara Ambrogio**, Università degli Studi di Torino

Novel RAS(ON) inhibitors overcome clinical resistance to KRAS G12C covalent blockade

**09:55 Francesco Cecconi**, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

The integrated role of selective autophagy in controlling cell division and metabolism

**10:15 Giorgia Foggetti**, Università Vita-Salute San Raffaele

Unveiling Novel Therapeutic Targets in Lung Adenocarcinoma

**10:35 Coffee Break**

**11:05 Keynote speaker:**

**Alessandra Boletta**, Università Vita-Salute San Raffaele  
Metabolic Reprogramming During Epithelial Transformation in the Kidney

**11:40 Federico Gulluni**, Università degli Studi di Torino

A phosphoinositide diffusion barrier prevents aneuploidy and tumorigenesis

**12:00 Marina Mapelli**, Istituto Europeo di Oncologia I.R.C.C.S. S.r.l.

Molecular cross-talk between epithelial polarity and fate determination maintains intestinal crypt integrity

**12:20 Giorgio Scita**, IFOM - Istituto Fondazione di Oncologia Molecolare, ETS

Tissue fluidification in breast cancer progression

**12:40 Selected short talks**

**Marta Massari**, Università degli Studi di Pavia

Discovery of the first-in-class inhibitor of nadph oxidases and their activities against cancer cell models

**Carmen Miano**, Istituto Nazionale di Biostrutture e Biosistemi  
ERBB2 overexpression bypasses negative feedback mechanisms triggered by EGFR overactivation in basal-like/triple-negative breast cells

**Giorgia Miloro**, Istituto Europeo di Oncologia I.R.C.C.S. S.r.l.  
Molecular tethers involved in inter-organelle communication controlling EGFR signaling

**Rosaria Noviello**, Università degli Studi di Napoli "Federico II"  
The clonal landscape of melanoma brain metastases

**Rosa Pennisi**, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia (FPO) - I.R.C.C.S.  
Exploiting alterations of membrane trafficking proteins to tackle metabolic reprogramming in cancer

**Martina Sarchi**, Università degli Studi di Pavia  
Mis-splicing of mitotic genes sensitizes malignant stem cells to CHK1 inhibition in SF3B1-mutant myeloid neoplasms

#### 13:40 Lunch

15:00 - 17:35

### SESSION 2: TRANSLATING DISCOVERIES INTO THE CLINICS

#### 15:00 Keynote Speaker

**Nicholas Papadopoulos**, Johns Hopkins University, Baltimore  
TBD

15:35 **Pier Paolo Di Fiore**, Istituto Europeo di Oncologia I.R.C.C.S. S.r.l.  
Endocytosis and cancer

15:55 **Francesca Fornari**, Alma Mater Studiorum Università di Bologna  
MicroRNA-494 induces metabolic reprogramming through G6pc targeting and represents a promising circulating biomarker for treatment stratification in hepatocellular carcinoma

16:15 **Gianluca Mauri**, IFOM - Istituto Fondazione di Oncologia Molecolare, ETS  
Blood based molecular profiles to monitor therapy response and MRD in CRC

#### 16:35 Selected short talks

**Amandine Billaud**, IFOM - Istituto Fondazione di Oncologia Molecolare, ETS  
Large meta-analysis and precision functional assays identify two FANCM regions where PTVs confer different risks for ER-negative and triple-negative breast cancer

**Giorgia Legiani**, Università degli Studi di Torino  
Targeting citron kinase catalytic activity for high grade brain tumors treatment

**Mirco Masi**, Fondazione Istituto Italiano di Tecnologia  
Intrinsic synergism of RAD51-BRCA2 disruptor RS-35d enantiomers as proof of concept for the novel within-pathway synthetic lethality paradigm in pancreatic cancer

**Tiziana Ottone**, Università degli Studi di Roma "Tor Vergata"  
Leukemic stem cells in flt3-itd-positive acute myeloid leukemia: disease reservoir and recurrence promoter

**Angelica Persia**, Ospedale Policlinico San Martino - IRCCS per l'Oncologia  
Metabolic and immunological effects of a "short-term modified fasting" (STMF) regimen in patients with a cancer diagnosis and receiving active treatment.

**Alice Romagnoli**, Università Politecnica delle Marche

Tackling translational control in cancer: structural and functional characterization of novel EIF4E-binding inhibitor

**17:35 Get together with drinks**

**DAY 2 – JUNE 27**

---

**08:30 Welcome**

**08:50 Introduction and greetings**

**09:00 - 10:00**

**SESSION 2: TRANSLATING DISCOVERIES INTO THE CLINICS**

**09:00 Lara Paracchini**, Humanitas Mirasole S.p.A.

Genomic instability analysis of DNA derived from Papanicolaou test for the early detection of ovarian cancer

**09:20 Antonella Sistigu**, Università Cattolica del Sacro Cuore

Epigenetics behind tumor immunology: IFN-I-KDM1B axis at the forefront of tumor progression and immune evasion

**09:40 Martina Sollini**, Università Vita-Salute San Raffaele

Radiopharmaceuticals targeting the tumor microenvironment

**10:00 Coffee Break**

**10:30 - 16:10**

**SESSION 3: IMMUNOLOGY AND IMMUNOTHERAPY**

**10:30 Keynote Speaker**

**Alexander Rudensky**, Ludwig center Memorial Sloan-Kettering Cancer Center, NYC

TBD

**11:05 Beatrice Bodega**, Università degli Studi di Milano

Transposable elements dynamics regulate T cell function within tumor microenvirontment

**11:25 Maria Chiara Bonini**, Università Vita-Salute San Raffaele

Genome editing of T cells to target solid tumors

**11:45 Stefano Casola**, IFOM - Istituto Fondazione di Oncologia Molecolare, ETS

B cell receptor and lymphomas: too good is bad, to weak is worse

**12:05 Selected short talks**

**Silvia Carnevale**, Università Humanitas

Neutrophils mediate protection against colitis and carcinogenesis by controlling bacterial invasion and IL-22 production by  $\gamma\delta$  T cells

**Verena Damiani**, Ospedale Pediatrico Bambino Gesù

High-throughput phenotypic screening platform reveals new anti-cancer immunomodulators to make high-risk neuroblastoma patients responsive to immunotherapy approaches

**Marco Notaro**, Università Vita-Salute San Raffaele

Genetically armed macrophages eliminate liver metastases by expanding and reprogramming tumor-reactive T cells

## 12:35 Lunch

14:05 **Maria Rosaria Galdiero**, Università degli Studi di Napoli "Federico II"

Neutrophils and Neutrophil Extracellular Traps: at the crossroads between inflammation and cancer

14:25 **Silvia Piconese**, Università degli Studi di Roma "La Sapienza"

Treg immunometabolism in cancer: T cell-intrinsic roles of BRCA1 in tumor immunity

14:45 **Antonio Sica**, Humanitas Mirasole S.p.A.

Metabolic Diversion of Immune Response in Cancer Patients

## 15:05 Selected short talks

**Domenico Supino**, Humanitas Mirasole S.p.A.

IL-1R8 acts as an immune checkpoint in CD8+ T cells, limiting cytokine-induced anti-tumor immune responses

**Mattia Toninelli**, IFOM - Istituto Fondazione di Oncologia Molecolare ETS

Charting the immune landscape and communication axes in metastatic colorectal cancer with spatial transcriptomics

## 15:35 Keynote Speaker

**Franco Locatelli**, Ospedale Pediatrico Bambino Gesù, Rome

TBD

## 16:10 - 17:00 CONCLUSIONS